Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Obama Uses Popularity To Make Case For Health Reform In Wisconsin
President Obama used his popularity Thursday at a town hall meeting in Green Bay, Wisc., in an effort to help make the case to Americans that a health care system overhaul needs to happen this year, Time reports.

Preventable Maternal Deaths Should Be Recognized As Women's Rights Violations, Opinion Piece Says
"Human rights organizations around the world are starting to demand that governments recognize preventable maternal death as a violation of women"s rights," Mary Robinson and Alicia Yamin, both advisory council members of the International Initiative on Maternal Mortality and Human Rights, write in a Boston Globe opinion piece. They add that with the "United Nations Human Rights Council"s June session just around the corner, governments have a chance to prove that they value women"s lives by taking concrete action on this issue." According to Robinson and Yamin, "[m]ore than one woman dies every minute from preventable causes in childbirth, and for every woman who dies as many as 30 others are left with lifelong, debilitating complications."They continue, "Moreover, when mothers die, children are at greater risk of dropping out of school, becoming malnourished and simply not surviving," adding, "Not only is maternal mortality and morbidity a global health emergency, but it triggers and aggravates cycles of poverty that cause generations of suffering and despair." The authors write, "Asserting that these preventable deaths are an issue of human rights does not mean that poor governments are going to be blamed for not doing what they cannot do." Instead, "understanding the profound injustice of disparities in maternal deaths makes it all the more urgent that donor states honor their funding commitments and that effective monitoring and accountability mechanisms are put in place to ensure that aid is going to the interventions that evidence has shown will save women"s lives," they add.According to Robinson and Yamin, Secretary of State Hillary Rodham Clinton 14 years ago at the Fourth World Conference on Women, then U.S. first lady, "declared that "women"s rights are human rights."" They add that Clinton recently has "passionately and eloquently affirmed [the Obama] administration"s commitment to women"s reproductive health needs around the world, and the Obama administration has called for increased funding for global health." They conclude, "As a new member of the Human Rights Council, the United States has the chance to lead the way in promoting a woman"s right to go through pregnancy and childbirth in safety and, just as important, to back up that assertion with adequate funding commitments" (Robinson/Yamin, Boston Globe, 6/4).
News of the day
European Medicines Agency Recommends First Marketing Authorisation For Cell-Based Medicine That Repairs Femoral Condyle Cartilage Defects
The European Medicines Agency has recommended the first marketing
Endocrinology

Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer's Disease At ICAD Annual Meeting

Pfizer Inc announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in combination with donepezil HCl tablets, in patients with Alzheimer"s disease.1,2 Based on the Phase 1 study results, PF-04360365 has advanced into Phase 2.3 Dimebon (latrepirdine), being co-developed by Pfizer and Medivation Inc., is in Phase 3 development.4 These data were presented this week at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD) in Vienna, Austria. A Phase 1, single-dose, dose escalation study (0.1 to 10 mg/kg) showed that the investigational compound PF-04360365 was well-tolerated in all patients, with no clinical or imaging evidence of vasogenic edema, and no new microhemorrhage or encephalitis reported to date in the ongoing follow-up period.1 In the Phase 1 dimebon (latrepirdine) study, results from a four-week, placebo-controlled trial of 24 patients on a stable dose of donepezil for at least 60 days showed that dimebon (latrepirdine) was well-tolerated when used in combination with donepezil.2 Alzheimer"s disease, a progressive and degenerative brain disease, is the most common type of dementia.5 Worldwide societal costs associated with dementia were estimated to be $315.4 billion in 2005.6 "Alzheimer"s disease is a destructive illness and Pfizer is committed to lifting the burden of the disease on patients and those who care for them," said Steven J. Romano, MD, vice president, Medical Affairs Head for Pfizer"s Primary Care Business Unit. "We are continuing to work with the global Alzheimer"s community to advance research in Alzheimer"s disease and currently have an investigational compound, dimebon (latrepirdine), in Phase 3 and two other compounds in Phase 2." Pfizer"s mAb PF-04360365 Well-Tolerated in Phase 1 Pfizer"s PF-04360365 is a highly selective and potent monoclonal antibody that targets the C-terminal end of the beta amyloid 1-40 peptide. It does not bind to the Amyloid Precursor Protein (APP), from which beta amyloid is derived, and which the body needs to function normally. This may contribute to a favorable risk/benefit profile, which will be further examined in long-term pivotal trials. This mAb has been designed to remove the toxic beta amyloid from the brain and potentially slow or halt Alzheimer"s disease progression. In the Phase 1 double-blind, placebo controlled trial, patients with mild-to-moderate Alzheimer"s disease (n=37) were randomized to one of five study groups to receive PF-04360365 as a single two-hour intravenous infusion ranging from 0.1-10 mg/kg (n=26) or placebo (n=11).1 These patients were monitored for one-year, and to date, four of the five study groups have completed the one year observation period. Results showed PF-04360365 was well-tolerated over this dose range. Routine safety lab values were unremarkable and there were no safety signals from brain Magnetic Resonance Imaging (MRIs), electrocardiograms (ECGs), cognitive scales or physical/neurological examinations.1 While the one-year observation period is still ongoing, the most common adverse events observed to date were upper respiratory tract infection (n=10), headache (n=9), back pain (n=6) and diarrhea (n=5), and all were mild to moderate in severity.1 "We are encouraged by these preliminary safety results and look forward to studying the safety, as well as the efficacy, of PF-04360365 in Phase 2 multiple dose trials," said Martin M. Bednar, MD, PhD, senior director and Pfizer clinical lead for the PF-04360365 program. "As we explore multiple compounds and mechanisms to treat Alzheimer"s disease, safety is of paramount importance given the vulnerability of the elderly population afflicted." Dimebon (latrepirdine) Shown to be Well-Tolerated in a Four-Week Combination Study In another study presented earlier in the week, Medivation and Pfizer announced that the investigational drug dimebon (latrepirdine) was well-tolerated when used in combination with donepezil HCl tablets. In this Phase 1, four-week, placebo-controlled safety study, 24 patients with Alzheimer"s disease on a stable dose of donepezil for at least 60 days were randomized to receive dimebon (latrepirdine) or placebo for two to four weeks.2 The first group of patients enrolled (dimebon, n=9, placebo, n=5) underwent gradual dose-titration in one-week intervals ranging from 2.5 mg three times daily (TID) up to 20 mg TID, over one month. The second group of patients (dimebon, n=6, placebo, n=4) titrated from 10 mg TID for one week to 20 mg TID for one week. No serious adverse events were reported in the study.2 The most commonly reported adverse events compared to placebo were fatigue (dimebon, n=3/15, placebo, n=0), abdominal distension (dimebon, n=2/15, placebo, n=0), fall (dimebon, n=2/15, placebo, n=0), hyperkalemia (dimebon, n=2/15, placebo, n=1/9) and nightmare (dimebon, n=2/15, placebo, n=0). These events were mild to moderate in severity and resolved with continued treatment.2 In addition to PF-04360365 and dimebon (latrepirdine), Pfizer is investigating several other compounds targeting different pathways for the treatment of Alzheimer"s disease. About Dimebon (latrepirdine) Dimebon (latrepirdine) is an investigational compound for the treatment of Alzheimer"s disease. Three Phase 3 trials are underway and two additional Phase 3 trials are scheduled to start later this year. CONCERT is a 12-month clinical trial examining the safety and efficacy of dimebon (latrepirdine) when added to donepezil in patients with mild to moderate Alzheimer"s disease, which recently began enrollment. CONCERT is designed to complement previous and ongoing studies evaluating the potential for dimebon (latrepirdine) to be used as monotherapy, as well as in combination with donepezil. Based on preclinical studies completed thus far, dimebon (latrepirdine) is thought to potentially stabilize or improve mitochondrial function in a way that prevents neurons from damage and dysfunction. The mechanism of action of dimebon (latrepirdine) is thought to be distinct from currently available Alzheimer"s medications. * Latrepirdine is the proposed generic (nonproprietary) name for dimebon. About Pfizer"s Commitment to Alzheimer"s Disease Alzheimer"s disease touches everyone. As the world population over age 65 grows rapidly, more people are at risk for this degenerative brain disease. Pfizer researchers are working diligently to find a way to help those affected by the disease. Building on a foundation of more than two decades of research, education and support for the global Alzheimer"s community, the company is investing heavily to advance understanding of the disease. Pfizer forms partnerships to develop novel therapies, supports policy initiatives that help ensure availability and access to treatments, and works collaboratively with academia and government on biomarker and diagnostic research initiatives to enable earlier Alzheimer"s diagnosis. Pfizer is studying different compounds targeting various central nervous system pathways that may be able to better treat Alzheimer"s disease symptoms and/or modify its underlying causes. Four novel compounds in clinical trials include: dimebon (latrepirdine), an investigational compound believed to impact mitochondrial function currently in Phase 3 trials; an antagonist of the Receptor for Advanced Glycation End-products (RAGE) in Phase 2 trials in partnership with the Alzheimer"s Disease Cooperative Study (ADCS) group; a highly selective humanized anti-amyloid monoclonal antibody in Phase 2 trials; and a phosphodiesterase-9A (PDE9A) inhibitor, moving into Phase 2 trials. Pfizer is co-developing dimebon (latrepirdine) with Medivation, and the RAGE development program is a Pfizer-TransTech collaboration. References 1. ICAD Submitted Abstract #O4-04-03. Safety and pharmacokinetics of the anti-amyloid monoclonal PF-04360365 following a single infusion in patients with mild-to-moderate Alzheimer"s disease: Preliminary results. Oral presentation. July 15, 2009: 3:30-3:45 p.m. M. Bednar - Presenter. 2009 International Conference on Alzheimer"s Disease (ICAD), Vienna, Austria. July 11-16, 2009. 2. ICAD Submitted Abstract #P1-254. A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer"s disease already receiving donepezil. Poster Session. July 12, 2009: 12:30-3:00 p.m. P Tariot - Presenter. 2009 International Conference on Alzheimer"s Disease (ICAD), Vienna, Austria. July 11-16, 2009. 3. ClinicalTrials.gov. Multiple IV Dose Study of PF-04360365 In Patients With Mild To Moderate Alzheimer"s Disease. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00722046. Accessed June 17, 2009. 4. ClinicalTrials.gov. Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer"s Disease on Donepezil (CONCERT). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00829374. Accessed June 17, 2009. 5 Alzheimer"s Association. What is Alzheimer"s? Accessed at: http://alz.org/alzheimers_disease_what_is_alzheimers.asp? Accessed June 9, 2009. 6. Wimo A, Winblad B, and Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer"s Dement. 2007;3:81-91. Pfizer Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009